University of Tasmania
Browse

File(s) under permanent embargo

The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase

journal contribution
posted on 2023-05-17, 10:00 authored by Nunan, J, Shearman, MS, Checler, F, Cappai, R, Evin, G, Beyreuther, K, Masters, CL, David SmallDavid Small
The β-amyloid protein (Aβ) is derived by proteolytic processing of the amyloid protein precursor (APP). Cleavage of APP by β-secretase generates a C-terminal fragment (APP-CTFβ), which is subsequently cleaved by γ-secretase to produce Aβ. The aim of this study was to examine the cleavage of APP-CTFβ by γ-secretase in primary cortical neurons from transgenic mice engineered to express the human APP-CTFβ sequence. Neurons were prepared from transgenic mouse cortex and proteins labelled by incubation with [35S]methionine and [35S]cysteine. Labelled APP-CTFβ and Aβ were then immunoprecipitated with a monoclonal antibody (WO2) specific for the transgene sequences. Approximately 30% of the human APP-CTFβ (hAPP-CTFβ) was converted to human Aβ (hAβ), which was rapidly secreted. The remaining 70% of the hAPP-CTFβ was degraded by an alternative pathway. The cleavage of hAPP-CTFβ to produce hAβ was inhibited by specific γ-secretase inhibitors. However, treatment with proteasome inhibitors caused an increase in both hAPP-CTFβ and hAβ levels, suggesting that the alternative pathway was proteasome-dependent. A preparation of recombinant 20S proteasome was found to cleave a recombinant cytoplasmic domain fragment of APP (APPcyt) directly. The study suggests that in primary cortical neurons, APP-CTFβ is degraded by two distinct pathways, one involving γ-secretase, which produces Aβ, and a second major pathway involving direct cleavage of APP-CTFβ within the cytoplasmic domain by the proteasome. These results raise the possibility that defective proteasome function could lead to an increase in Aβ production in the AD brain.

History

Publication title

European Journal of Biochemistry: The Febs Journal

Volume

268

Issue

20

Pagination

5329-5336

ISSN

0014-2956

Department/School

Menzies Institute for Medical Research

Publisher

Blackwell Publishing Ltd

Place of publication

9600 Garsington Rd, Oxford, England, Oxon, Ox4 2Dg

Rights statement

The definitive published version is available online at: http://www3.interscience.wiley.com/

Repository Status

  • Restricted

Socio-economic Objectives

Clinical health not elsewhere classified

Usage metrics

    University Of Tasmania

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC